[Therapy of neonatal infection caused by group B beta-hemolytic Streptococcus].
Expectant therapy for early Group B Streptococcus onset septicemia must provide coverage against other microorganism, such as L. Monocytogenes, H. Influenzae and S. Pneumoniae. It is possible to administer a combination of antimicrobial agents with activity against all or the most likely pathogens. Thus initial expectant therapy includes a broad spectrum semisynthetic penicillin (e.g. ampicillin) and an aminoglycoside (e.g. netilmicin). Vancomicin, teicoplanin and cefotaxime may also be used. Supportive therapy consists on temperature control, i.v. administration of fluids, acid-base balance and electrolytes monitoring, seizures control and ventilation. IV immunoglobulins, granulocyte and serum transfusion are also used. The G-Colony Stimulating Factor (G-CSF, filgastrim) usage is also reported.
D000367:Age Factors; D000900:Anti-Bacterial Agents; D001803:Blood Transfusion; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D016179:Granulocyte Colony-Stimulating Factor / Q000276:immunology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007167:Immunotherapy; D007231:Infant, Newborn; D008991:Monitoring, Physiologic; D012121:Respiration, Artificial; D013290:Streptococcal Infections / Q000628:therapy*; D013292:Streptococcus agalactiae
D000900:Anti-Bacterial Agents; D016756:Immunoglobulins, Intravenous; D016179:Granulocyte Colony-Stimulating Factor
La terapia dell'infezione neonatale da streptococco beta-emolitico di gruppo B.